194 results on '"Venugopal, Balaji"'
Search Results
52. Retrohepatic Caval Leiomyosarcoma Antesitum Resection: A Case Report and a Review of Literature
53. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
54. PLLBA-01 PEMBROLIZUMAB (PEMBRO) VS PLACEBO AS POST NEPHRECTOMY ADJUVANT THERAPY FOR PATIENTS (pts) WITH RENAL CELL CARCINOMA (RCC): RANDOMIZED, DOUBLE-BLIND, PHASE 3 KEYNOTE-564 STUDY
55. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
56. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
57. Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
58. Additional file 3 of The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer ��� a study protocol
59. Additional file 2 of The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer ��� a study protocol
60. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
61. Influence of tumor size in the progression of venous tumor thrombus in renal cell carcinoma: A 7-year single-center experience.
62. SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.
63. Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies:\ud prospective cardiac magnetic resonance imaging in patients with cancer
64. Advanced Penile Cancer Presenting With Renal Failure
65. A non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) in the United Kingdom.
66. Cardiotoxicity and myocardial hypoperfusion associated with anti‐vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer
67. Prevalence of Ankyloglossia among Children Reporting with Speech Pathology to District Early Intervention Centre (DEIC)- An Observational Study
68. Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).
69. Knowledge, Attitudes and Practices towards Oral Health among School Teachers in Chengalpattu Taluk, Kanchipuram District Tamilnadu
70. Inferior vena cava obstruction as a rare manifestation of bronchopulmonary sequestration
71. Interesting case of left subclavian pseudoaneurysm in a child managed successfully
72. MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE MARKERS OF ANGIOGENESIS INHIBITOR-INDUCED CARDIOTOXICITY
73. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
74. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
75. Challenges in ex-vivo resection of caval leiomyosarcoma
76. Sugar amide-pyrrolidine catalyst for the asymmetric Michael addition of ketones to nitroolefins
77. Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.
78. Radium-223 treatment for metastatic prostate cancer: One year data in a single institution experience.
79. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin
80. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer
81. Adapting the Design of the Ongoing RAMPART Trial in Response to External Evidence: An Example for Trials Which Take Many Years to Run and Report
82. ChemInform Abstract: Sugar Amide-Pyrrolidine Catalyst for the Asymmetric Michael Addition of Ketones to Nitroolefins
83. Axitinib in advanced renal cell carcinoma: Outcomes following pazopanib or sunitinib.
84. A first-in-human phase i and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
85. Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.
86. Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
87. A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).
88. A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
89. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
90. Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect
91. Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.
92. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
93. Coexistent Malignant Melanoma and Renal Cell Carcinoma
94. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
95. Late Recurrences of Renal Cell Carcinoma at Unusual Sites: Implications for Patient Management.
96. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes
97. Conversion from cyclosporin to tacrolimus in a patient with prolonged acute tubular necrosis
98. Preclinical evaluation of a novel drug delivery system for cisplatin
99. Preclinical evaluation of a novel drug delivery system for cisplatin
100. Preclinical evaluation of a novel drug delivery system for cisplatin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.